Competitor Analysis: Emerging Diabetes Drugs
Product description
The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT inhibitors, glucokinase activators, 11beta-HSD1 inhibitors and many others. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. In addition, the report lists company-specific R&D pipelines of emerging diabetes drugs in R&D. Competitor projects are listed in a tabular format providing information on:
Index
Corporate Emerging Diabetes Drugs R&D Pipelines
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT inhibitors, glucokinase activators, 11beta-HSD1 inhibitors and many others. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. In addition, the report lists company-specific R&D pipelines of emerging diabetes drugs in R&D. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
- Sodium-Dependent Glucose Co-Transporter (SGLT) Inhibitors
- 11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
- Glucokinase Activators (GKA)
- Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists
- Sirtuin (SIRT) Activators
- Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors
- Glucagon Receptor (GCGR) Antagonists
- Glucocorticoid Receptor (GCGR) Antagonists
- Novel Insulin Sensitizers
- G-Protein Coupled Receptor 119 (GPR119) Agonists
- Other Drugs Augmenting GLP-1 Secretion: GPR40, GR120 & TGR5 Agonists
- Other Glucometabolic Approaches
- Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors
- Other Metabolic Approaches
- FGF-21-Receptor Agonists
- Anti-Inflammatory Approaches
- Induction of Immune Tolerance
- Pancreatic Beta Cell Protection & Regeneration
- Pancreatic Islet Cell Transplantation
- Various Antidiabetic Approaches
Corporate Emerging Diabetes Drugs R&D Pipelines
- 7TM Pharma
- Abbott
- AdiStem
- Advinus Therapeutics
- Alize Pharma
- ALLOZYNE
- Ambrx
- Amgen
- Amylin Pharmaceuticals
- Andromeda
- Arena Pharmaceuticals
- Array BioPharma
- Astellas Pharma
- AstraZeneca
- Bayhill Therapeutics
- Betagenon
- BHV Pharma
- Biocon
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS)
- Catabasis Pharmaceuticals
- Cellonis Biotechnologies
- ChemoCentryx
- Columbia University Medical Center
- Connexios Life Sciences
- Cortendo
- CureDM Group
- Cyclacel
- Cytos Biotechnology
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Debiopharm
- DiaKine Therapeutics
- Diamedica
- Diamyd Medical
- Eli Lilly
- Ensemble Discovery
- Evotec
- Exsulin
- Forest Laboratories
- Genzyme
- Geron Corp
- GlaxoSmithKline (GSK)
- Helsinn
- High Point Pharmaceuticals
- Immunocore
- Incyte
- Inovio
- Intercept Pharmaceuticals
- Ipsen
- ISIS Pharmaceuticals
- Japan Tobacco
- Johnson & Johnson (J&J)
- Kalypsys
- Karo Bio
- Kotobuki
- Les Laboratoires Servier (Servier)
- Lexicon Pharmaceuticals
- LG Life Science
- Ligand Pharmaceuticals
- Living Cell Technologies (LCT)
- MacroGenics
- MedImmune
- Melior Discovery
- Mesoblast
- Metabolex
- Merck & Co.
- Mercury Therapeutics
- MicroIslet
- Mitsubishi Tanabe Pharma
- Neurocrine Biosciences
- National Institutes of Health (NIH)
- Novartis
- NovImmune
- Omni Bio Pharmaceutical
- Ortho-McNeil-Janssen Pharmaceuticals (OMJPI)
- Ortho McNeil (J&J)
- Osiris therapeutics
- Pfizer
- PharmaFrontier
- Pinnacle
- Piramal Life Sciences
- Poxel
- Rigel Pharmaceuticals
- Roche
- Sanofi-Aventis
- S2 Therapeutics
- Santarus
- Sanwa Kagaku Kenkyusho
- Sirona Biochem
- Takeda Pharmaceutical
- Targacept
- Teva Pharmacetical Industries
- Theracos
- Tolera Therapeutics
- Tolerx
- TransTech Pharma
- VeroScience
- Versartis
- VIA Pharmaceuticals
- ViaCyte
- Vitae Pharmaceuticals
- Wellstat Therapeutics
- XOMA
- Yuhan Co.
- Zydus Cadila
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
